naftopidil has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Kudou, T; Ohinata, M; Suzuki, A | 1 |
| Cai, SL; Chen, SP; Chen, SY; Ding, Q; Gu, XJ; Huo, HX; Li, NC; Li, X; Na, YQ | 1 |
1 trial(s) available for naftopidil and Chronic Disease
| Article | Year |
|---|---|
[Clinical application of alpha1 adrenoceptor antagonist Naftopidil to the treatment of chronic non-bacterial prostatitis].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatitis | 2006 |
1 other study(ies) available for naftopidil and Chronic Disease
| Article | Year |
|---|---|
[Effects of alpha1 adrenoceptor antagonist, naftopidil, on non-bacterial chronic pelvic pain syndrome in patients with lower urinary tract syndrome: evaluation of its efficacy using NIH-CPSI after 4-week treatment].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Chronic Disease; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Pelvic Pain; Piperazines; Prostatitis; Quality of Life; Surveys and Questionnaires; Syndrome; Time Factors | 2010 |